Pleomorphic adenoma of the salivary glands
Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
At the time the article was last revised Ashesh Ishwarlal Ranchod had no financial relationships to ineligible companies to disclose.View Ashesh Ishwarlal Ranchod's current disclosures
Pleomorphic adenomas of the salivary glands, also known as benign mixed tumors (see below), are the most common salivary gland tumors. The salivary glands are the most common site of pleomorphic adenomas.
On imaging, they commonly present as well-circumscribed rounded masses, most commonly located within the parotid gland, hypoechoic on ultrasound, and bright on T2WI with homogeneous enhancement on MRI.
Historically pleomorphic adenomas have also been called benign mixed tumors, however, this name is now discouraged. It was previously thought that these were a form of teratoma, however, it is now clear that the neoplasm forms from a single layer of germ cells and is purely epithelial in nature 15.
Pleomorphic adenomas account for 70-80% of benign salivary gland tumors and are especially common in the parotid gland, comprising the majority of all parotid gland tumors (see below) 1,6. Patients are typically middle-aged and the incidence is slightly higher in females than males (2:1) 1,13. The oncogenic simian virus (SV40) may play a role in onset or progression and prior head and neck irradiation is a risk factor for the development of these tumors 13,14.
Patients typically present with a smooth, painless, enlarging mass.
As the name suggests, pleomorphic adenomas are composed of a mixture of variable histology. They contain both epithelial and myoepithelial (mesenchymal) tissues, with mixed histology. They appear encapsulated and well-circumscribed however the pseudocapsule is delicate and incomplete with microscopic extensions reaching beyond it, accounting for the high risk of recurrence when these tumors are enucleated (see below) 5,6.
The gross appearance depends upon the relative proportion of epithelial elements and a stromal component which may range from myxoid to cartilage. Tumors with a prominent cartilaginous matrix have a bluish-grey opalescent appearance.
Three histological types have been described:
myxoid (hypocellular): most common, highest rate of recurrence
Distribution among the salivary glands is as follows 1:
parotid gland: 84% 1
commoner in the superficial lobe
submandibular gland: 8%
minor salivary glands: 6.5%
widely distributed including the nasal cavity, pharynx, larynx, trachea 5
sublingual glands: 0.5%
They are less common in salivary glands other than the parotid but remain the most common benign tumor of each gland.
On all modalities, these tumors typically appear as rounded masses with well-defined, "bosselated" or "polylobulated" borders (many small undulations, not truly lobulated). They are most commonly located within the parotid gland, particularly the superficial lobe.
When they arise from the deep lobe of the parotid they can appear entirely extra parotid, seen in the prestyloid parapharyngeal space, without a fat plane between it and the parotid, and widen the stylomandibular tunnel. Pleomorphic adenomas can also arise from salivary rest cells in the parapharyngeal space itself without connection to the parotid gland.
They are typically hypoechoic and may show posterior acoustic enhancement.
Ultrasound is also useful in guiding a biopsy (both FNAC and core biopsies) but needs to be carried out with care to avoid facial nerve damage 8,9.
When small, they have homogeneous attenuation and prominent enhancement. When larger, they can be heterogeneous with less prominent enhancement, foci of necrosis, and possible delayed enhancement. Small regions of calcification are common 1,10.
The signal characteristics are homogeneous when the tumor is small. Larger tumors may be heterogeneous.
T1: usually of low intensity
characteristically of very high intensity (especially myxoid type) 6
often have a rim of decreased signal intensity on T2-weighted images representing the surrounding fibrous capsule
T1 C+ (Gd): usually demonstrates homogeneous enhancement
FDG-PET may show some uptake; SUV more than 3 in 25% of cases 11.
Treatment and prognosis
Surgical excision is curative, however, as the tumor is poorly encapsulated (despite imaging suggesting otherwise) there is a significant rate of recurrence in the tumor bed. Exact rates of recurrence vary widely depending on series and surgical technique (1-50%) 1.
Historically these tumors were removed by enucleation, resulting in recurrence rates of 20-45% 6.
To minimize this occurrence, no open surgical biopsy should be performed. Rather, a partial (superficial) or total parotidectomy ensures a wide margin. The facial nerve should be spared 4,6. Using this approach, the recurrence rate has reduced dramatically to 1-4% 6.
Percutaneous ultrasound biopsy (both FNAC and core biopsy) can be performed safely and is associated with very low tumor seeding rates and without facial nerve injury provided meticulous technique is used 8,9.
When in the minor salivary glands, a 5 mm margin should be obtained. These tumors do not invade into periosteum, thus bone need not be resected 4.
When tumor bed recurrences occur, they can be extremely difficult to control, with management options including monitoring only, surgery, or radiotherapy.
There is a small risk of malignant transformation into a carcinoma ex-pleomorphic adenoma which is proportional to the time the lesion is in situ (1.5% in the first 5 years, 9.5% after 15 years), thus excision is recommended in essentially all cases. Additional risk factors for malignancy include advanced age, large size, radiation therapy, and recurrent tumors 2,6. In addition to carcinoma ex-pleomorphic adenoma, true malignant mixed tumors of the salivary glands usually arise from pre-existing pleomorphic adenomas 1,3. Metastasizing pleomorphic adenoma is the third type of malignant mixed tumor of salivary glands and is the rarest. It presents with metastases to lung, bone, and soft tissues despite having 'benign' histology 1.
When in the parotid gland consider:
- 1. Thoeny H. Imaging of Salivary Gland Tumours. Cancer Imaging. 2007;7(1):52-62. doi:10.1102/1470-7330.2007.0008 - Pubmed
- 2. Kato H, Kanematsu M, Mizuta K, Ito Y, Hirose Y. Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland: Radiologic-Pathologic Correlation with MR Imaging Including Diffusion-Weighted Imaging. AJNR Am J Neuroradiol. 2008;29(5):865-7. doi:10.3174/ajnr.A0974 - Pubmed
- 3. Kim, H.-S & Cho, H.J. & Chung, Y.-T & Park, S.-A & Kim, J.-M. (2008). Carcinosarcoma (true malignant mixed tumor) of the parotid gland - A report of a case with small cell carcinoma as the carcinoma component. Korean Journal of Pathology. 42. 175-180 link
- 4. Jonathan Pedlar, John W. Frame. Oral and Maxillofacial Surgery. (2001) ISBN: 9780443060175 - Google Books
- 5. Motoori K, Takano H, Nakano K, Yamamoto S, Ueda T, Ikeda M. Pleomorphic Adenoma of the Nasal Septum: MR Features. AJNR Am J Neuroradiol. 2000;21(10):1948-50. PMC7974307 - Pubmed
- 6. Moonis G, Patel P, Koshkareva Y, Newman J, Loevner L. Imaging Characteristics of Recurrent Pleomorphic Adenoma of the Parotid Gland. AJNR Am J Neuroradiol. 2007;28(8):1532-6. doi:10.3174/ajnr.A0598 - Pubmed
- 7. Zeynel A. Karcioğlu. Orbital Tumors. (2005) ISBN: 9780387213217 - Google Books
- 8. Howlett D, Menezes L, Lewis K, Moody A, Violaris N, Williams M. Sonographically Guided Core Biopsy of a Parotid Mass. AJR Am J Roentgenol. 2007;188(1):223-7. doi:10.2214/AJR.05.1549 - Pubmed
- 9. Wan Y, Chan S, Chen Y et al. Ultrasonography-Guided Core-Needle Biopsy of Parotid Gland Masses. AJNR Am J Neuroradiol. 2004;25(9):1608-12. PMC7976420 - Pubmed
- 10. Lev M, Khanduja K, Morris P, Curtin H. Parotid Pleomorphic Adenomas: Delayed CT Enhancement. AJNR Am J Neuroradiol. 1998;19(10):1835-9. PMC8337714 - Pubmed
- 11. Uchida Y, Minoshima S, Kawata T et al. Diagnostic Value of FDG PET and Salivary Gland Scintigraphy for Parotid Tumors. Clin Nucl Med. 2005;30(3):170-6. doi:10.1097/00003072-200503000-00005 - Pubmed
- 12. Christe A, Waldherr C, Hallett R, Zbaeren P, Thoeny H. MR Imaging of Parotid Tumors: Typical Lesion Characteristics in MR Imaging Improve Discrimination Between Benign and Malignant Disease. AJNR Am J Neuroradiol. 2011;32(7):1202-7. doi:10.3174/ajnr.A2520 - Pubmed
- 13. Bokhari M & Greene J. Pleomorphic Adenoma. 2023. - Pubmed
- 14. Gündüz A, Yeşiltaş Y, Shields C. Overview of Benign and Malignant Lacrimal Gland Tumors. Curr Opin Ophthalmol. 2018;29(5):458-68. doi:10.1097/ICU.0000000000000515 - Pubmed
- 15. Bradley P. The Recurrent Pleomorphic Adenoma Conundrum. Curr Opin Otolaryngol Head Neck Surg. 2018;26(2):134-41. doi:10.1097/MOO.0000000000000435 - Pubmed